Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...

New 5-year data on the efficacy and safety of Sotyktu show consistent results for adults with moderate to severe psoriasis. Rates of serious adverse events were similar to other psoriasis treatments.

Sotyktu (deucravacitinib) can cause side effects that range from mild to serious. More common side effects include infection, acne, and mouth sores. If Sotyktu side effects become difficult to ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

In the POETYK PsA-2 trial, 54.2% of Sotyktu-treated patients achieved ACR20 at Week 16 vs. 39.4% on placebo. Sotyktu improved PsA disease activity, including clinical signs, extra-articular ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) trial of its drug candidate Sotyktu (deucravacitinib) for plaque ...

Bristol Myers (BMY) Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. The POETYK PsA-2 ...

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque ...

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis.